This edition includes new reporting on how simultaneous budget and staffing cuts across federal, state, and local agencies slowed this year’s response to a nationwide cyclospora outbreak. We’re also covering BARDA’s expansion of its SMART Antiviral Prize to $150 million as nine teams advance toward treatments for dengue, Zika, West Nile, and chikungunya, and new seroprevalence data showing a quarter of cats near California dairy farms carry H5N1 antibodies.
FEATURED
Weeks Lost: How Budget and Staffing Cuts Slowed the Cyclospora Response at Every Level
Internal Michigan emails obtained by the New York Times show investigators waited twelve days for Taco Bell supply chain records that a delayed FDA traceability rule would have required within 24 hours, one symptom of a food-safety system weakened by an estimated $5.8 billion cut to CDC grant funding since last year. CDC’s FoodNet program made cyclospora surveillance optional for states in July 2025, and its national case count stood at just 145 on July 1 even as Michigan alone was independently tracking more than 12,000 cases. The pattern extends to the local level as well: one West Virginia county has seen its sanitarian staff cut in half over two years, and Kentucky’s food safety workforce is down 30 to 50 percent due to federal grant reductions.
BARDA Expands Antiviral Prize Competition to $150 Million as Nine Teams Advance in Race to Fill Critical Drug Gap
BARDA announced Aug. 26 that nine teams have won Concept Stage awards of $2.5 million each in its SMART Antiviral Prize, targeting broad-spectrum treatments for dengue, Zika, West Nile, and chikungunya, and expanded the competition’s total value from $100 million to $150 million. The winners now advance to a Hit-to-Lead stage opening in September worth up to $7.5 million per award, with the full timeline running through 2030 toward an FDA Investigational New Drug filing. Dengue alone infects an estimated 400 million people annually worldwide, and no FDA-approved broad-spectrum antiviral currently exists for any of the four targeted viral families, even as the United States has seen rising locally acquired cases in states including Florida and Texas.
Cats Near Dairy Farms Carry H5N1 Antibodies at Striking Rates, Study Finds
A study in CDC’s Emerging Infectious Diseases found that 25 percent of cats living within two kilometers of an active H5N1 dairy farm outbreak in California’s Tulare County tested positive for antibodies against the virus, compared with an overall rate of 4.1 percent across all 73 cats sampled. With an estimated case-fatality rate near 90 percent in infected cats, the researchers argue surviving animals likely undercount true exposure, and that cat surveillance could serve as a sentinel system for nearby H5N1 activity. The finding carries added weight because cats carry both avian and human-type influenza receptors, a candidate mixing vessel for viral reassortment, and documented cat-to-human H5N1 transmission has already occurred three times in the United States.
BIOSECURITY + BIOPREPAREDNESS
75 Hospitals and Counting: Federal Program Expands the Nation’s Frontline Defense Against Deadly Pathogens
ASPR and NETEC announced a second round of STAND Awards on Sep. 1, adding 21 hospitals across 16 states and territories to the National Special Pathogen System and bringing the total network to 75 facilities, each receiving up to $500,000 to meet federal Level 2 treatment standards for diseases like Ebola and MERS. The cohort joins 54 hospitals selected in a first round announced in January 2026, expanding specialized care beyond the small number of Level 1 centers that have historically borne the burden during outbreaks.
South Korea’s Bioterrorism Response Training Program Shows Strong Gains
A Korea Disease Control and Prevention Agency evaluation of its 2025 bioterrorism and emerging infectious disease training program found that trainees’ practical confidence using Level C protective equipment rose 87.6 percent, far outpacing academic knowledge gains, after the 14-course curriculum drew 631 applications for 230 slots and graduated 234 people. All 47 trainees who completed the dedicated Level C equipment course passed its hands-on evaluation, evidence the authors say supports expanding scenario-based, practice-oriented training over lecture-based instruction.
A Proposed Biosafety Rewrite Could Reshape Oversight for Every US Lab
A draft NIH policy released Aug. 19 would replace the decades-old Guidelines for Research Involving Recombinant DNA Molecules, expanding federal biosafety oversight beyond genetically modified organisms to cover any wild-type pathogen, toxin, or prion that poses a biohazard. The proposal would also compress the incident-reporting window from 30 days to 24 hours and formalize Biosafety Officer duties including active verification of containment practices, with public comments due October 19.
A Blueprint For Managing The World’s Most Dangerous Research
A policy review by UNSW Sydney’s Ruihan Zhang identifies five overlapping threat pathways in dual-use research of concern, including accidental release, insider misuse, and cyberattacks on lab systems, and proposes eleven governance recommendations built on existing WHO and ISO frameworks rather than a new regulatory body. The review cautions that poorly calibrated oversight carries real costs, citing an estimate linking Denmark’s 2008 Biosecurity Act to a sharp drop in biotechnology patents.
POLICY + GOVERNMENT
When the Nation’s Top Health Official Becomes the Outbreak’s Biggest Obstacle
Two people, including an infant, have died in Pennsylvania’s measles outbreak, the state’s first measles-associated deaths in 35 years, but HHS Secretary Robert F. Kennedy Jr. suggested on social media the deaths “may even have been altogether fabricated,” even after Pennsylvania’s health secretary confirmed both had tested positive for measles. Kennedy compounded the damage by repeating debunked vaccine-autism claims during a call with Governor Josh Shapiro, at a moment when national kindergarten MMR coverage has fallen below the roughly 95 percent threshold needed for herd immunity.
MEDICAL COUNTERMEASURES
A Faster Route to Better mRNA Medicines Might Start With a Single Molecular Swap
A study published in Nature finds that swapping the mRNA modification used in current COVID-19 vaccines, N1-methylpseudouridine, for an alternative called N4-acetylcytidine let ribosomes move nearly twice as fast, avoiding the molecular pile-ups that reduce protein output and introduce errors. Both modifications performed similarly on inflammation safety, but the ac4C version consistently produced more, better-made protein, raising the possibility of future mRNA vaccines that generate a stronger immune response from a smaller dose.
New Blood Test Could Cut Sepsis Diagnosis From Days To Hours
A Stanford and Penn State team funded by NIH describes in Science Advances a new diagnostic platform, STREAM, that identifies bloodstream pathogens and their antibiotic susceptibility directly from whole blood in as little as 6.75 hours, compared with the two to seven days standard blood culture requires. Tested against 104 patient samples, the platform’s species identification matched conventional lab results 96.15 percent of the time and remained reliable at bacterial concentrations some existing rapid tests miss entirely.
The Shingles Vaccine May Do More Than Prevent Shingles
A Nature Medicine study of more than 72,000 Americans found that people who received the Shingrix shingles vaccine spent 9 percent more cumulative time free of a composite cardiovascular endpoint than those who received the older Zostavax vaccine, using the 2017-2018 rollout as a natural experiment to reduce healthy-vaccinee bias. Ischemic heart disease burden was 10 percent lower and heart failure 12 percent lower among Shingrix recipients, a pattern researchers suspect may trace to the vaccine’s adjuvant dampening long-term inflammation rather than shingles prevention itself.
GSK’s mRNA Flu Vaccine Heads to Phase III
GSK announced Sep. 1 it will advance its dual-antigen mRNA flu vaccine candidate, which targets neuraminidase alongside the hemagglutinin protein most vaccines rely on, into Phase III trials after positive Phase II results in 971 adults presented at the OPTIONS XIII influenza conference. The move follows Moderna’s August 5 FDA approval of mFlusiva, the first mRNA flu vaccine to reach market, and positions GSK as a second entrant pursuing a mechanism Moderna previously paused in its own pipeline.
SELECT AGENTS + PRIORITY PATHOGENS
When the Clock Starts Ticking: Uganda’s Ebola Response Sets a Global Benchmark
A new Early Action Review published in CDC’s Emerging Infectious Diseases finds Uganda met all three of WHO’s 7-1-7 outbreak response benchmarks during a cross-border Bundibugyo virus outbreak declared jointly with the DRC on May 15, detecting it in six days, notifying authorities the same day, and completing early response actions within two days. The outbreak Uganda contained is still raging next door: as of Aug. 31, the DRC had reported more than 6,100 cases and nearly 2,950 deaths, the second-largest Ebola outbreak on record.
SURVEILLANCE + DETECTION
How A Tribal Health System Built A Wastewater Early-Warning System From Scratch
A CDC Emerging Infectious Diseases study documents two years of wastewater surveillance by the Yukon-Kuskokwim Health Corporation in Bethel, Alaska, where on-site PCR testing gave up to ten days of advance warning on influenza A and flagged rising COVID-19 and RSV activity before clinical data confirmed it, with SARS-CoV-2 detection reaching 95.9 percent sensitivity. The Tribal health organization used the data to time vaccine campaigns and is now expanding the system to remote villages and piloting wastewater-based tuberculosis surveillance.
ONE HEALTH
Kansas State’s Zoonotic Disease Research Hub Lands $11.4 Million NIH Renewal
Kansas State University has secured $11.4 million in renewed NIH funding to extend its Center on Emerging and Zoonotic Infectious Diseases through April 2031, building on a first five-year phase that generated 30 awards worth roughly $18 million from more than 100 proposals. The center’s second phase will pursue four research tracks, including Lyme disease, influenza severity in obesity, and a coronavirus vaccine strategy using genetic deoptimization, while continuing to operate shared laboratory cores for the wider regional research community.
ENVIRONMENTAL FLUX
Mosquitoes, Microbes, and a Warming World: The Infectious Disease Threats Reshaping Global Health
An updated Institut Pasteur threat assessment finds the Asian tiger mosquito has now colonized nearly four-fifths of mainland France, driving more than 830 locally acquired chikungunya and dengue cases in 2025 among people who had not traveled to any tropical region. The assessment also warns that antimicrobial resistance, already causing 1.3 million deaths annually, could climb to 39 million deaths by 2050, while separate modeling projects African yellow fever deaths could rise 11 to 25 percent by mid-century.
Venezuela Joins the Expanding Map of Oropouche
Venezuelan researchers report in CDC’s Emerging Infectious Diseases the country’s first confirmed Oropouche virus cases, seven infections across two states identified through expanded arboviral testing in early 2025, with genomic sequencing linking the isolates to the same lineage driving Cuba’s 2024 outbreak. None of the patients had recent travel history, pointing to local transmission, and the authors warn that Oropouche’s clinical overlap with Venezuela’s ongoing dengue epidemic likely means many cases are going undetected.
MEASLES OUTBREAK
Pennsylvania’s Measles Outbreak Reaches 379 Cases, Prompting Updated Vaccination Guidance
Pennsylvania confirmed 379 measles cases across 28 counties between April and August 21, prompting a Health Alert Network update in which Secretary of Health Debra Bogen directed clinicians to accelerate MMR vaccination schedules and maintain heightened suspicion for the disease. The department now recommends an early, supplementary MMR dose for infants aged 6 to 11 months living in or visiting counties with active community transmission, in addition to the routine two-dose series.
Coalition of 210+ Health Groups Mounts Unprecedented Pushback Against White House Vaccine Executive Order
More than 210 medical, patient advocacy, and public health organizations, including the American Medical Association, the American Academy of Pediatrics, and autism advocacy groups, issued a joint statement August 17 opposing a White House executive order that advises reducing and spacing out recommended childhood vaccines. The coalition called the order’s timing, arriving amid an active measles surge, unsupported by science and warned it would leave children less protected.
ALSO READING
DRC starts Ebola vaccinations for health workers – Medscape
Aid group MSF opens new Ebola treatment centre in eastern Congo – Reuters
USDA confirms new H5N1 avian flu cases in poultry, dairy cattle – CIDRAP
The biological security education landscape in 2025 and beyond – Journal of Biosafety and Biosecurity
Advancing biothreat detection with novel spray-based technology developed for defense applications – Battelle
FDA issues Emergency Use Authorization for generic drug to prevent New World Screwworm in cattle – FDA
CDC Director fails first test of independence from RFK Jr. – Inside Medicine
When the federal vaccine process falters, good science cannot stop – CIDRAP
This content was compiled from Global Biodefense’s original reporting and drafted with Claude AI assistance for summarizing and editing.